Literature DB >> 4037525

Pharmacokinetic studies on antituberculosis regimens in humans. I. Absorption and metabolism of the compounds used in the initial intensive phase of the short-course regimens: single administration study.

G Acocella, R Conti, M Luisetti, E Pozzi, C Grassi.   

Abstract

The absorption and metabolism of streptomycin, isoniazid, rifampicin, and pyrazinamide were evaluated after administration of each drug alone and in combination. In the combination sessions, isoniazid, rifampicin, and pyrazinamide were administered orally, either individually or in a single fixed-ratio triple preparation. The results have shown that the pattern of absorption and metabolism (acetyl-isoniazid, desacetyl-rifampicin, and pyrazinoic acid) found after administration of each drug alone did not differ from that found after administration of the drugs in free and fixed combination. The 3 orally administered drugs given in a fixed combination resulted in a reduction of the order of 50% of the total number of tablets to be ingested.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4037525     DOI: 10.1164/arrd.1985.132.3.510

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  4 in total

1.  Pharmacokinetics of pyrazinamide and its metabolites in healthy subjects.

Authors:  C Lacroix; T P Hoang; J Nouveau; C Guyonnaud; G Laine; H Duwoos; O Lafont
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

2.  Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis.

Authors:  Y Dong; X Zhao; B N Kreiswirth; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

Review 3.  Clinical pharmacokinetic considerations in the treatment of patients with leprosy.

Authors:  K Venkatesan
Journal:  Clin Pharmacokinet       Date:  1989-06       Impact factor: 6.447

4.  Assessment of the Efficacy of New Anti-Tuberculosis Drugs.

Authors:  Denis A Mitchison; Geraint R Davies
Journal:  Open Infect Dis J       Date:  2008-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.